Hunan Er-Kang Pharmaceutical Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Qingrong Sun
Chief executive officer
CN¥335.7k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5.1yrs |
| CEO ownership | n/a |
| Management average tenure | 5.1yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Subdued Growth No Barrier To Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267) With Shares Advancing 27%
Sep 30
Hunan Er-Kang Pharmaceutical (SZSE:300267) Has Debt But No Earnings; Should You Worry?
Sep 26What Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) 28% Share Price Gain Is Not Telling You
Aug 08Health Check: How Prudently Does Hunan Er-Kang Pharmaceutical (SZSE:300267) Use Debt?
Jun 03Pinning Down Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) P/S Is Difficult Right Now
Mar 27CEO
Qingrong Sun (38 yo)
5.1yrs
Tenure
CN¥335,700
Compensation
Mr. Qingrong Sun is General Manager of Hunan Er-Kang Pharmaceutical Co., Ltd from November 14, 2019 and serves as Director from November 14, 2022. He joined Hunan Er-Kang Pharmaceutical Co., Ltd. in July 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Non-Independent Director | 5.1yrs | CN¥335.70k | no data | |
| CFO & Non Independent Director | no data | CN¥389.10k | no data | |
| Deputy GM & Non Independent Director | no data | CN¥535.10k | no data | |
| Deputy GM & Board Secretary | 4.8yrs | CN¥514.20k | 0.0017% CN¥ 102.6k | |
| Deputy General Manager | no data | CN¥422.70k | no data | |
| Deputy General Manager | 5.1yrs | CN¥365.30k | no data |
5.1yrs
Average Tenure
42.5yo
Average Age
Experienced Management: 300267's management team is seasoned and experienced (5.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Non-Independent Director | 2.1yrs | CN¥335.70k | no data | |
| CFO & Non Independent Director | 5.1yrs | CN¥389.10k | no data | |
| Deputy GM & Non Independent Director | 6.3yrs | CN¥535.10k | no data | |
| Chairman of the Board | no data | CN¥512.60k | 41.38% CN¥ 2.4b | |
| Independent Director | 5.1yrs | CN¥150.00k | no data | |
| Independent Director | 5.1yrs | CN¥150.00k | no data | |
| Chairman of Supervisory Board | 3.6yrs | no data | no data | |
| Independent Director | 2.1yrs | CN¥150.00k | no data | |
| Non-Employee Supervisor | 2.1yrs | no data | no data | |
| Supervisor | 2.1yrs | no data | no data |
3.6yrs
Average Tenure
50yo
Average Age
Experienced Board: 300267's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 06:57 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hunan Er-Kang Pharmaceutical Co., Ltd is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Jing Qiang | China International Capital Corporation Limited |